Bonness Enterprises Inc. held its stake in shares of Johnson & Johnson (NYSE:JNJ) during the third quarter, according to its most recent disclosure with the SEC. The fund owned 44,438 shares of the company’s stock at the end of the third quarter. Johnson & Johnson makes up 4.4% of Bonness Enterprises Inc.’s holdings, making the stock its 4th largest position. Bonness Enterprises Inc.’s holdings in Johnson & Johnson were worth $5,250,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Americafirst Capital Management LLC bought a new position in shares of Johnson & Johnson during the second quarter worth approximately $101,000. Tuttle Tactical Management LLC bought a new position in shares of Johnson & Johnson during the second quarter worth approximately $103,000. Lenox Wealth Management Inc. increased its position in shares of Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock worth $118,000 after buying an additional 190 shares during the last quarter. Thomas J. Herzfeld Advisors Inc. increased its position in shares of Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock worth $122,000 after buying an additional 690 shares during the last quarter. Finally, NCM Capital Management Group Inc. bought a new position in shares of Johnson & Johnson during the second quarter worth approximately $127,000. Institutional investors and hedge funds own 64.13% of the company’s stock.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Shares of Johnson & Johnson (NYSE:JNJ) traded down 1.05% during midday trading on Wednesday, hitting $111.30. The stock had a trading volume of 11,166,987 shares. Johnson & Johnson has a one year low of $94.28 and a one year high of $126.07. The firm’s 50-day moving average price is $115.97 and its 200-day moving average price is $118.40. The firm has a market capitalization of $302.80 billion, a PE ratio of 19.54 and a beta of 0.75.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.66 by $0.02. Johnson & Johnson had a return on equity of 25.30% and a net margin of 22.03%. The firm earned $17.80 billion during the quarter, compared to analysts’ expectations of $17.71 billion. During the same period last year, the firm posted $1.49 EPS. The business’s revenue was up 4.2% on a year-over-year basis. On average, equities analysts predict that Johnson & Johnson will post $6.72 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be issued a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 2.88%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.29. The ex-dividend date is Friday, November 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 56.64%.

TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Position Maintained by Bonness Enterprises Inc.” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/30/johnson-johnson-jnj-position-maintained-by-bonness-enterprises-inc.html.

A number of research analysts recently commented on JNJ shares. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price objective for the company in a research note on Monday, August 22nd. RBC Capital Markets set a $133.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research note on Wednesday, November 9th. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, September 20th. Argus restated a “buy” rating and set a $145.00 price objective on shares of Johnson & Johnson in a research note on Friday, October 21st. Finally, BTIG Research restated a “neutral” rating on shares of Johnson & Johnson in a research note on Thursday, August 25th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $121.03.

In other Johnson & Johnson news, Director Charles Prince purchased 875 shares of the company’s stock in a transaction that occurred on Friday, October 21st. The stock was purchased at an average cost of $114.11 per share, with a total value of $99,846.25. Following the acquisition, the director now directly owns 26,520 shares of the company’s stock, valued at approximately $3,026,197.20. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.11% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.